Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Oligoarticular juvenile idiopathic arthritis

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare inflammatory rheumatic disease characterized by juvenile onset arthritis that affects fewer than 5 joints during the first 6 months after disease onset.

ORPHA:85410

Classification level: Disorder

Synonym(s):
  • Pauciarticular chronic arthritis
  • Oligoarticular JIA

Source: PubMed ID 28418334 17336654 30375520

Prevalence: 1-5 / 10 000

Inheritance: Multigenic/multifactorial

Age of onset: Childhood

ICD-10: M08.4

ICD-11: FA24.0

UMLS: C2931171

MeSH: C536312

GARD: 4261

Summary
Epidemiology

The incidence of juvenile idiopathic arthritis in Caucasians is 8.3/100,000. Oligoarticular juvenile idiopathic arthritis is the most common form in North America and Europe, comprising 30% to 60% of children with juvenile idiopathic arthritis. It affects girls more than boys and is rare in individuals of African, Native American or Sourthern Asian descent.

Clinical description

The disease is typically asymmetrical, affecting between one to four joints, predominantly those of the lower limbs (knee or foot) although the wrist and elbows could be rarely affected. Onset occurs between the ages of 2 and 4. The disease is divided into persistent oligoarthritis, in which there is no more than 4 joints involved after the first six months of illness, and extended oligoarthritis, in which there is involvement of more than 4 joints involved after the first six months. Pain is not a constant feature in young children and the most common reasons for seeking medical advice are an increase in the volume of the joint and/or limping. The association of this form of arthritis with nonsymptomatic iridocyclitis (no pain or visible redness) is a specific feature that is present in a third of cases. Systemic manifestations other than uveitis are characteristically absent. Therefore, fever, rash, or other constitutional symptoms suggest a different diagnosis.

Etiology

The etiology is not currently known. All juvenile idiopathic arthritis subtypes are most likely complex genetic traits as they lack single-gene, Mendelian patterns of inheritance. Inherited risk factors for both disease susceptibility and disease severity have been reported; the highly polymorphic HLA genes confer the strongest genetic effects.

Diagnostic methods

Diagnosis is based on the clinical manifestations, and exclusion of other potential causes. The presence of iridocyclitis and/or antinuclear antibodies without fever or psoriasis are strong diagnostic indicators. Exclusion criteria includes presence of systemic arthritis, psoriasis, ankylosing spondylarthritis, enthesitis and arthritis, sacroiliitis with an inflammatory enteropathy or acute anterior uveitis in the patient or a first-degree relative. In addition, HLA B27-positivity in males with onset of arthritis after 6 years of age and presence of rheumatoid factor IgM must be excluded.

Differential diagnosis

Differential diagnosis principally includes the other subtypes of juvenile idiopathic arthritis as well as Lyme disease, inflammatory bowel disease, pigmented villonodular synovitis, malignancy, plant thorn synovitis, septic arthritis, osteomyelitis, or tuberculosis.

Management and treatment

First step of treatment is non-steroidal anti-inflammatory agent (NSAID) , but their efficacy is quite rare. Intra-articular glucocorticoids injections are often necessary and effective. Methotrexate and, if ineffective, biologics are recommended for children with disease that extends to involve five or more joints or require repeat injections.

Prognosis

Several long-term complications may occur, the most frequent and significant ones being temporomandibular joint arthritis with retrognatism, uveitis complications (glaucoma or synechia), leg-length discrepancy in case of delayed diagnosis. Arthritis may extend to involve five or more joints within several years of diagnosis.

Last update: April 2020 - Expert reviewer(s): Dr Chantal DESLANDRE
A summary on this disease is available in Français, Español, Deutsch, Italiano, Nederlands Ελληνικά, Русский
Detailed information

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

General public
Article for general public
Norsk (2016) - PRINTO/PRES
עברית (2016) - PRINTO/PRES
Polski (2016) - PRINTO/PRES
Latviešu (2016) - PRINTO/PRES
Deutsch (2016) - PRINTO/PRES
Ελληνικά (2016) - PRINTO/PRES
English (2016) - PRINTO/PRES
Español (2016) - PRINTO/PRES
Nederlands (2016) - PRINTO/PRES
Türkçe (2016) - PRINTO/PRES
ไทย (2016) - PRINTO/PRES
বাংলা (2016) - PRINTO/PRES
Slovenščina (2016) - PRINTO/PRES
Slovenčina (2016) - PRINTO/PRES
Dansk (2016) - PRINTO/PRES
Српски (2016) - PRINTO/PRES
Čeština (2016) - PRINTO/PRES
Русский (2016) - PRINTO/PRES
Hrvatski (2016) - PRINTO/PRES
中文 (2016) - PRINTO/PRES
Română (2016) - PRINTO/PRES
Magyar (2016) - PRINTO/PRES
Italiano (2016) - PRINTO/PRES
العربية (2016) - PRINTO/PRES
Português (2016) - PRINTO/PRES
Guidelines
Emergency guidelines
Français (2025.pdf) - Orphanet Urgences
Clinical practice guidelines
English (2022) - Arthritis Rheumatol
Español (2020.pdf) - Asoc Española de Pediatría
Diagnostic Keys
Français (2022) - Les clés du diagnostic Logo FSMR
Disease review articles
Review article
English (2025) - N Engl J Med
Disability
Disability factsheet
Patient-Centered Outcome Measures (PCOMs)
Access questionnaires assessing quality of life in this disease (English)
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.